MOONLAKE IMMUNOTHERAPEUTICS (MLTX) Stock Price, Quote, News and Overview
NASDAQ:MLTX - Nasdaq - KY61559X1045 - Common Stock - Currency: USD
MLTX Quote, Performance and Key Statistics
MOONLAKE IMMUNOTHERAPEUTICS
NASDAQ:MLTX (1/24/2025, 5:20:01 PM)
After market: 45.7 0 (0%)45.7
-1.18 (-2.52%)
The current stock price of MLTX is 45.7 USD. In the past month the price decreased by -12.35%. In the past year, price decreased by -20.08%.
MLTX Latest News, Press Releases and Analysis
Goldman Sachs Thinks Mid-Cap Biotech MoonLake Could Soar Over 80%: Is Retail Watching Closely?
Oppenheimer has included MoonLake among its top biotech picks for 2025, alongside Capricor, Gilead, Kymera, Praxis, and Prothena.
MoonLake Immunotherapeutics Becomes Oversold (MLTX)
MLTX Crosses Below Key Moving Average Level
MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab
MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab
New trials in three new indications have been initiated with the Nanobody® sonelokimab: Phase 3 VELA-TEEN trial in adolescent hidradenitis suppurativa...
MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11
MoonLake Immunotherapeutics to host a Capital Markets Updateon Wednesday, September 11 ZUG, Switzerland, September 9, 2024 – MoonLake Immunotherapeutics...
MLTX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.84 | 300.94B | ||
| AMGN | AMGEN INC | 14.33 | 148.05B | ||
| GILD | GILEAD SCIENCES INC | 21.01 | 115.99B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 862 | 113.22B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.88 | 74.26B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.80B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.95B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.47B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.64B | ||
| NTRA | NATERA INC | N/A | 22.13B | ||
| BIIB | BIOGEN INC | 8.95 | 21.30B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.52B |
Related stock screener links
About MLTX
Company Profile
Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. The company is headquartered in Zug, Zug and currently employs 50 full-time employees. The company went IPO on 2020-10-20. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The firm develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.
Company Info
MOONLAKE IMMUNOTHERAPEUTICS
Dorfstrasse 29
Zug ZUG CH
Employees: 50
Company Website: https://moonlaketx.com/
Investor Relations: https://ir.moonlaketx.com/
Phone: 41415108022
MLTX FAQ
What is the stock price of MLTX?
The current stock price of MLTX is 45.7 USD.
What is the symbol for MOONLAKE IMMUNOTHERAPEUTICS stock?
The exchange symbol of MOONLAKE IMMUNOTHERAPEUTICS is MLTX and it is listed on the Nasdaq exchange.
On which exchange is MLTX stock listed?
MLTX stock is listed on the Nasdaq exchange.
Is MLTX a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for MLTX, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of MLTX.
Does MLTX stock pay dividends?
MLTX does not pay a dividend.
What is the Price/Earnings (PE) ratio of MLTX?
MLTX does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.29).
What is the Short Interest ratio of MLTX stock?
The outstanding short interest for MLTX is 15.07% of its float.
MLTX Technical Analysis
MLTX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to MLTX. MLTX has a great financial health rating, but its profitability evaluates not so good.
MLTX Financial Highlights
Over the last trailing twelve months MLTX reported a non-GAAP Earnings per Share(EPS) of -1.29. The EPS decreased by -35.79% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -15.59% | ||
| ROE | -16.54% | ||
| Debt/Equity | 0 |
MLTX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to MLTX. The Buy consensus is the average rating of analysts ratings from 23 analysts.